The NLRP3 inflammasome as a target for sensorineural hearing loss

被引:18
|
作者
Gregory, Grace E. [1 ,2 ,3 ]
Munro, Kevin J. [4 ,5 ]
Couper, Kevin N. [2 ,3 ]
Pathmanaban, Omar N. [1 ,2 ,3 ,6 ]
Brough, David [1 ,2 ,3 ]
机构
[1] Univ Manchester, Fac Biol Med & Hlth, Sch Biol Sci, Div Neurosci,Manchester Acad Hlth Sci Ctr, Manchester, England
[2] Univ Manchester, Geoffrey Jefferson Brain Res Ctr, Manchester Acad Hlth Sci Ctr, Northern Care Alliance NHS Grp, Manchester, England
[3] Univ Manchester, Lydia Becker Inst Immunol & Inflammat, Manchester, England
[4] Univ Manchester, Manchester Ctr Audiol & Deafness, Sch Hlth Sci, Manchester, England
[5] Manchester Univ Hosp NHS Fdn Trust, Manchester Acad Hlth Sci Ctr, Manchester, England
[6] Salford Royal Hosp NHS Fdn Trust, Manchester Ctr Clin Neurosci, Dept Neurosurg, Salford, England
基金
英国医学研究理事会;
关键词
Sensorineural hearing loss; Inflammation; Cochlea; NLRP3; inflammasome; Interleukin-1;
D O I
10.1016/j.clim.2023.109287
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Sensorineural hearing loss is the most common type of hearing loss in adults and occurs due to damage of the inner ear caused by a range of factors including ageing, excessive noise, toxins, and cancer. Auto-inflammatory disease is also a cause of hearing loss and there is evidence that inflammation could contribute to hearing loss in other conditions. Within the inner ear there are resident macrophage cells that respond to insults and whose activation correlates with damage. The NLRP3 inflammasome is a multi-molecular pro-inflammatory protein complex that forms in activated macrophages and may contribute to hearing loss. The aim of this article is to discuss the evidence for the NLRP3 inflammasome and associated cytokines as potential therapeutic targets for sensorineural hearing loss in conditions ranging from auto-inflammatory disease to tumour-induced hearing loss in vestibular schwannoma.
引用
收藏
页数:5
相关论文
共 50 条
  • [1] The NLRP3 Inflammasome as a Pharmacological Target
    Marchetti, Carlo
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2019, 74 (04) : 285 - 296
  • [2] Mitochondrial dysfunction in hearing loss: Oxidative stress, autophagy and NLRP3 inflammasome
    Li, Peipei
    Li, Shen
    Wang, Le
    Li, Hongmin
    Wang, Yang
    Liu, Hongbing
    Wang, Xin
    Zhu, Xiaodan
    Liu, Zhangsuo
    Ye, Fanglei
    Zhang, Yuan
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2023, 11
  • [3] Role of the NLRP3 Inflammasome in Preeclampsia
    Shirasuna, Koumei
    Karasawa, Tadayoshi
    Takahashi, Masafumi
    FRONTIERS IN ENDOCRINOLOGY, 2020, 11
  • [4] NLRP3 inflammasome in ischemic stroke: As possible therapeutic target
    Alishahi, Masoumeh
    Farzaneh, Maryam
    Ghaedrahmati, Farhoodeh
    Nejabatdoust, Armin
    Sarkaki, Alireza
    Khoshnam, Seyed Esmaeil
    INTERNATIONAL JOURNAL OF STROKE, 2019, 14 (06) : 574 - 591
  • [5] The NLRP3 inflammasome: an emerging therapeutic target for chronic pain
    Ruixiang Chen
    Chengyu Yin
    Jianqiao Fang
    Boyi Liu
    Journal of Neuroinflammation, 18
  • [6] The NLRP3 inflammasome: an emerging therapeutic target for chronic pain
    Chen, Ruixiang
    Yin, Chengyu
    Fang, Jianqiao
    Liu, Boyi
    JOURNAL OF NEUROINFLAMMATION, 2021, 18 (01)
  • [7] NLRP3 Ubiquitination-A New Approach to Target NLRP3 Inflammasome Activation
    Akther, Mahbuba
    Haque, Md Ezazul
    Park, Jooho
    Kang, Tae-Bong
    Lee, Kwang-Ho
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (16)
  • [8] The NLRP3 inflammasome and stroke
    Tong, Yeqing
    Ding, Zhi-Hong
    Zhan, Fa-Xian
    Cai, Li
    Yin, Xiaoxv
    Ling, Jin-Lian
    Ye, Jian-Jun
    Hou, Shuang-Yi
    Lu, Zuxun
    Wang, Zhi-Hong
    Liu, Jia-Fa
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2015, 8 (04): : 4787 - 4794
  • [9] Inhibiting the NLRP3 Inflammasome
    El-Sharkawy, Lina Y.
    Brough, David
    Freeman, Sally
    MOLECULES, 2020, 25 (23):
  • [10] Vasculitis and the NLRP3 inflammasome
    Hamzaoui, Kamel
    Hamzaoui, Agnes
    CURRENT OPINION IN RHEUMATOLOGY, 2024, 36 (01) : 9 - 15